GRF

GRF Grifols, S.A.

Stock · MCE · Spain · Healthcare · ES0171996087

NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Grifols, S.A., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price 11.25 EUR -0.31%

52-week range 8.43 – 11.70

Dividend yield0.71%

Market cap7.7B

NowoTrade score 20 Grade A

Price history

Daily prices in EUR.

Updated 07 Nov 2026 12:17. Information, not advice.

Results

Next results 25 Feb 2027 in 110 days · 11:00

Last results 0.15 vs 0.24 estimated 27 Jul 2026 · Miss -38.1%

Beat the estimate 3 of 12 8 missed · 1 in line

Average surprise +11.5% reported against the estimate, last 12 quarters

Earnings per share: estimate and reported

Estimate Reported: beat Reported: miss In line

Quarterly results

Date	EPS estimate	EPS reported	Surprise	Result
25 Feb 2027 11:00	—	—	—	Upcoming
27 Jul 2026 20:00	0.24	0.15	-38.1%	Miss
28 Jul 2025 18:00	0.24	0.19	-18.9%	Miss
30 Jul 2024 14:00	0.14	0.14	-1.9%	Miss
27 Jul 2023 08:00	0.13	0.09	-29.0%	Miss
27 Feb 2022 19:00	0.22	-0.06	-127.3%	Miss
29 Jul 2021 08:00	0.23	0.24	+0.7%	In line
04 May 2021 01:00	0.19	0.17	-11.1%	Miss
26 Feb 2021 18:00	0.19	0.24	+25.7%	Beat
05 Nov 2020 02:00	0.26	0.32	+23.6%	Beat
30 Jul 2020 08:00	0.07	0.31	+341.6%	Beat
21 Apr 2020 08:00	0.26	0.22	-14.6%	Miss
27 Feb 2020 15:00	0.32	0.28	-12.9%	Miss
29 Oct 2019 03:00	0.28	0.25	-8.3%	Miss
31 Jul 2019 03:00	0.28	0.29	+2.8%	Beat
07 May 2019 05:00	0.22	0.22	-2.0%	Miss
28 Feb 2019 02:00	0.27	0.21	-20.1%	Miss
05 Nov 2018 05:00	0.26	0.26	-3.0%	Miss
27 Jul 2018 02:00	0.26	0.29	+9.3%	Beat
03 May 2018 02:00	0.23	0.24	+1.7%	Beat
28 Feb 2018 03:00	0.25	0.24	-5.6%	Miss
02 Nov 2017 03:00	0.25	0.24	-2.9%	Miss
28 Jul 2017 03:00	0.27	0.24	-9.0%	Miss
03 May 2017 02:00	0.24	0.25	+0.8%	In line
28 Feb 2017 02:00	0.22	0.24	+9.3%	Beat
08 Nov 2016 02:00	0.23	0.25	+11.1%	Beat
28 Jul 2016 06:00	0.22	0.23	+6.1%	Beat
05 May 2016 03:00	0.21	0.20	-1.7%	Miss
29 Feb 2016 03:00	0.27	0.22	-17.2%	Miss
04 Nov 2015 06:00	0.23	0.24	+4.1%	Beat
30 Jul 2015 01:00	0.21	0.22	+2.4%	Beat
07 May 2015 06:00	0.21	0.22	+3.2%	Beat
26 Feb 2015 08:00	0.23	0.24	+4.1%	Beat
04 Nov 2014 02:00	0.21	0.21	-0.3%	In line
31 Jul 2014 01:00	0.23	0.21	-9.2%	Miss
06 May 2014 16:00	0.20	0.21	+9.7%	Beat
27 Feb 2014 09:00	0.16	0.16	+4.9%	Beat
05 Nov 2013 14:00	0.14	0.13	-13.5%	Miss
31 Jul 2013 01:00	0.15	0.17	+9.3%	Beat
02 May 2013 15:00	0.10	0.17	+65.9%	Beat
01 Mar 2013 06:00	0.15	0.10	-30.5%	Miss
31 Oct 2012 09:00	0.12	0.11	-11.8%	Miss
31 Jul 2012 13:00	0.14	0.11	-17.1%	Miss
15 May 2012 14:00	0.10	0.12	+26.3%	Beat
28 Feb 2012 07:00	0.13	—	-103.7%	—
11 Nov 2011 07:00	0.14	0.06	-57.8%	Miss
28 Jul 2011 19:00	0.09	-0.03	-134.6%	Miss
04 May 2011 20:00	0.10	0.07	-30.0%	Miss
24 Feb 2011 07:00	0.09	0.04	-52.9%	Miss
20 Dec 2010 12:00	0.09	0.07	-15.9%	Miss

Annual results · EUR

Year	Revenue	Change	Net income	Net margin	EPS	EPS change	Free cash flow
2025	7.5B	+4.3%	402M	5.3%	0.59	+156.5%	624M
2024	7.2B	+9.4%	157M	2.2%	0.23	+155.6%	530M
2023	6.6B	+8.7%	42M	0.6%	0.09	-71.0%	-93M
2022	6.1B	—	185M	3.1%	0.31	—	-394.3M

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Day Week Month

Price history in EUR, by day
Period	Opening price	High	Low	Closing price	Change	Volume
22 May 2025	9.50	9.59	9.21	9.34	-1.93%	2,291,304
21 May 2025	9.37	9.56	9.37	9.53	+1.66%	3,161,958
20 May 2025	9.26	9.37	9.18	9.37	+2.29%	2,285,137
19 May 2025	9.05	9.16	8.95	9.16	+1.78%	2,865,313
16 May 2025	8.72	9.07	8.61	9.00	+4.60%	2,730,060
15 May 2025	8.60	8.76	8.44	8.60	-0.19%	2,465,530
14 May 2025	8.94	9.09	8.60	8.62	-3.51%	3,422,758
13 May 2025	8.64	9.09	8.57	8.93	+6.46%	6,225,664
12 May 2025	8.14	8.41	8.01	8.39	+3.22%	2,293,295
09 May 2025	8.16	8.19	8.08	8.13	-0.34%	1,656,040
08 May 2025	8.22	8.25	8.07	8.16	-0.15%	1,555,037
07 May 2025	8.30	8.31	8.16	8.17	-2.16%	1,434,501
06 May 2025	8.56	8.57	8.32	8.35	-2.29%	1,293,616
05 May 2025	8.59	8.62	8.51	8.55	+0.21%	898,848
02 May 2025	8.52	8.58	8.36	8.53	+2.82%	1,410,988
30 Apr 2025	8.39	8.54	8.21	8.29	-0.79%	1,880,268
29 Apr 2025	8.49	8.51	8.27	8.36	-1.46%	1,320,862
28 Apr 2025	8.59	8.63	8.45	8.48	-0.35%	1,233,545
25 Apr 2025	8.49	8.57	8.45	8.51	+0.78%	969,460
24 Apr 2025	8.38	8.48	8.32	8.45	+0.64%	1,138,023
23 Apr 2025	8.52	8.54	8.38	8.39	+0.50%	1,552,578
22 Apr 2025	8.10	8.35	8.02	8.35	+3.52%	1,259,989
17 Apr 2025	8.15	8.24	8.02	8.07	-1.78%	1,049,575
16 Apr 2025	8.20	8.21	7.98	8.21	-1.23%	1,436,887
15 Apr 2025	8.17	8.32	8.13	8.32	+1.79%	1,797,583

Prices in EUR, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

Grifols (BME:GRF) Stock Price Trails Q3 Results As Debt Questions Linger (opens in a new tab) Simply Wall St. · 03 Nov 2026 19:11
Grifols Beats Q3 Revenue Forecasts as Immunoglobulin Demand Supports Profit Growth (opens in a new tab) InvestorsHub · 03 Nov 2026 11:17
Grifols SA (GRFS) Q3 2026 Earnings Call Highlights: Biopharma Growth Accelerates as Margin ... (opens in a new tab) GuruFocus.com · 03 Nov 2026 05:03
Grifols (GRFS) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 03:58
Grifols Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 02 Nov 2026 20:12
Grifols Q3 revenue exceeds estimates as immunoglobulin sales drive growth (opens in a new tab) Investing.com · 02 Nov 2026 18:20
Grifols (BME:GRF) Stock Still Looks Cheap Based On Current Earnings (opens in a new tab) Simply Wall St. · 27 Oct 2026 06:07
Plasma Demand Supports Grifols, S.A.’s (GRFS) Path Back to Financial Strength (opens in a new tab) Insider Monkey · 23 Oct 2026 15:35
Are Options Traders Betting on a Big Move in Grifols Stock? (opens in a new tab) Zacks · 07 Oct 2026 13:54
Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings (opens in a new tab) Simply Wall St. · 26 Sep 2026 16:14

Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close: 11.28 EUR
Market cap: 7.7B
Dividend yield: 0.71%
5-year average yield: 1.33%
Payout ratio: 12%
Last dividend: 0.1500 EUR · 02 Dec 2026
Next ex-dividend date: 02 Dec 2026
Exchange: MCE
Country: Spain
Sector: Healthcare
Industry: Drug Manufacturers - General
Currency: EUR

Dividends

Ex-dividend date	Per share
30 Jun 2026	0.0824 EUR
11 Aug 2025	0.1500 EUR
03 Jun 2021	0.3643 EUR
26 Oct 2020	0.1616 EUR
02 Dec 2019	0.2000 EUR
07 Jun 2019	0.1451 EUR
30 Nov 2018	0.2000 EUR
01 Jun 2018	0.2040 EUR
01 Dec 2017	0.1800 EUR
30 May 2017	0.1356 EUR
05 Dec 2016	0.1800 EUR
02 Jun 2016	0.1326 EUR

Why this score

How the score is made up
Part of the score	Points	Why
Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble.	3.0 / 25	Yield of 0.7% on today's price
Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover.	5.3 / 25	Dividend uses 12% of free cash flow (3-year average)
Dividend growth How many years in a row the dividend has risen, and how fast.	3.4 / 15	Dividend growth of 3.6% a year
Quality Return on equity, net margin and how stable the margins are.	6.5 / 15	ROE of 7%
Valuation Free cash flow yield and the P/E against its sector.	7.1 / 10	P/E 15.8 against 31.1 for its sector
Analysts How far the analysts' average target is from today's price.	5.0 / 5	Analysts' target is +35% from the price

Score capped at 50: the dividend was cut recently
Heavy debt: net debt is 5.0× EBITDA
The dividend paid in the last 12 months is lower than in the 12 before

Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 95% of the figures (grade A). Warnings take 12 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.

Figures

Valuation
Figure	Value	Reading	Sector median
P/E (trailing)	15.84×	Fair	31.09×
P/E (forward)	10.13×	Good	14.98×
Price / book	1.32×	Good	3.94×
Price / sales	1.01×	Good	3.37×
EV / EBITDA	10.86×	Fair	12.96×
Free cash flow yield	2.5%	Fair	2.6%

Quality
Figure	Value	Reading	Sector median
Gross margin	38.2%	Fair	59.2%
Operating margin	21.1%	Good	7.4%
Net margin	6.4%	Fair	3.4%
Return on equity	7.3%	Weak	5.7%
Return on assets	4.5%	Fair	3.6%

Growth
Figure	Value	Reading	Sector median
Revenue growth / year	7.5%	Fair	10.8%
EPS growth / year	23.9%	Good	10.2%

Financial health
Figure	Value	Reading	Sector median
Debt / equity	1.12×	Fair	0.46×
Net debt / EBITDA	5.04×	Weak	1.5×
Interest cover	2.17×	Weak	3.26×
Current ratio	2.33×	Good	2.35×

Dividends
Figure	Value	Reading	Sector median
Payout of earnings	11.6%	Good	0%
Payout of free cash flow	65.8%	Fair	30.1%
Payout of free cash flow (3 years)	12.2%	Good	—
Dividend growth / year	3.6%	Fair	7.1%
Years of rising dividends	0	Weak	2

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Follow GRF and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in